Список литературы к Главе 20

24. Lin M.T., Mosier S.L., Thiess M., Beierl K.F., Debeljak M., Tseng L.H. et al. Clinical validation of KRAS, BRAF, and EGFR mutation detection using next­generation sequencing // Am. J. Clin. Pathol. 2014. Vol. 141. P. 856–866.

25. Oh E., Choi Y.L., Kwon M.J., Kim R.N., Kim Y.J., Song J.Y. et al. Comparison of accuracy of whole­exome sequencing with formalin­fixed paraffin­embedded and fresh frozen tissue samples // PLoS One. 2015. Vol. 10. Article ID e0144162.

26. Williams C., Pontén F., Moberg C., Söderkvist P., Uhlén M., Pontén J. et al. A high frequency of sequence alterations is due to formalin fixation of archival specimens // Am. J. Pathol. 1999. Vol. 155. P. 1467–1471.

27. Edlund K., Larsson O., Ameur A., Bunikis I., Gyllensten U., Leroy B. et al. Data­driven unbiased curation of the TP53 tumor suppressor gene mutation database and validation by ultradeep sequencing of human tumors // Proc. Natl Acad. Sci. USA. 2012. Vol. 109. P. 9551–9556.

28. Lykke­Andersen S., Jensen T.H. Nonsense­mediated mRNA decay: an intricate machinery that shapes transcriptomes // Nat. Rev. Mol. Cell Biol. 2015. Vol. 16. P. 665–677.

29. Leroy B., Ballinger M.L., Baran­Marszak F., Bond G.L., Braithwaite A., Concin N. et al. Recommended guidelines for validation, quality control, and reporting of TP53 variants in clinical practice // Cancer Res. 2017. Vol. 77. P. 1250–1260.

30. Pal K., Bystry V., Reigl T., Demko M., Krejci A., Touloumenidou T. et al. GLASS: assisted and standardized assessment of gene variations from Sanger sequence trace data // Bioinformatics. 2017. Vol. 33. P. 3802–3804.

31. Kantorova B., Malcikova J., Smardova J., Pavlova S., Trbusek M., Tom N. et al. TP53 mutation analysis in chronic lymphocytic leukemia: comparison of different detection methods // Tumour Biol. 2015. Vol. 36. P. 3371–3380.

32. Lazarian G., Tausch E., Eclache V., Sebaa A., Bianchi V., Letestu R. et al. TP53 mutations are early events in chronic lymphocytic leukemia disease progression and precede evolution to complex karyotypes // Int. J. Cancer. 2016. Vol. 139. P. 1759–1763.

33. Sutton L.A., Ljungström V., Mansouri L., Young E., Cortese D., Navrkalova V. et al. Targeted next­generation sequencing in chronic lymphocytic leukemia: a high­throughput yet tailored approach will facilitate implementation in a clinical setting // Haematologica. 2015. Vol. 100. P. 370–376.

34. Jethwa A., Hüllein J., Stolz T., Blume C., Sellner L., Jauch A. et al. Targeted resequencing for analysis of clonal composition of recurrent gene mutations in chronic lymphocytic leukaemia // Br. J. Haematol. 2013. Vol. 163. P. 496–500.

35. Akbari M., Hansen M.D., Halgunset J., Skorpen F., Krokan H.E. Low copy number DNA template can render polymerase chain reaction error prone in a sequence­dependent manner // J. Mol. Diagn. 2005. Vol. 7. P. 36–39.

36. Hiatt J.B., Pritchard C.C., Salipante S.J., O’Roak B.J., Shendure J. Single molecule molecular inversion probes for targeted, high­ accuracy detection of low­frequency variation // Genome Res. 2013. Vol. 23. P. 843–854.

37. Kinde I., Wu J., Papadopoulos N., Kinzler K.W., Vogelstein B. Detection and quantification of rare mutations with massively parallel sequencing // Proc. Natl Acad. Sci. USA. 2011. Vol. 108. P. 9530–9535.

38. Chen G., Mosier S., Gocke C.D., Lin M.T., Eshleman J.R. Cytosine deamination is a major cause of baseline noise in next­generation sequencing // Mol. Diagn. Ther. 2014. Vol. 18. P. 587–593.

39. den Dunnen J.T., Dalgleish R., Maglott D.R., Hart R.K., Greenblatt M.S., McGowan­Jordan J. et al. HGVS recommendations for the description of sequence variants: 2016 update // Hum. Mutat. 2016. Vol. 37. P. 564–569.

40. Bouaoun L., Sonkin D., Ardin M., Hollstein M., Byrnes G., Zavadil J. et al. TP53 variations in human cancers: new lessons from the IARC TP53 database and genomics data // Hum. Mutat. 2016. Vol. 37. P. 865–876.

41. Leroy B., Anderson M., Soussi T. TP53 mutations in human cancer: database reassessment and prospects for the next decade // Hum. Mutat. 2014. Vol. 35. P. 672–688.

42. Lek M., Karczewski K.J., Minikel E.V., Samocha K.E., Banks E., Fennell T. et al. Analysis of protein­coding genetic variation in 60,706 humans // Nature. 2016. Vol. 536. P. 285–291.

43. Dumont P., Leu J.I., Della Pietra A.C., George D.L., Murphy M. The codon 72 polymorphic variants of p53 have markedly different apoptotic potential // Nat. Genet. 2003. Vol. 33. P. 357–365.

44. Kochethu G., Delgado J., Pepper C., Starczynski J., Hooper L., Krishnan S. et al. Two germ line polymorphisms of the tumour suppressor gene p53 may influence the biology of chronic lymphocytic leukaemia // Leuk. Res. 2006. Vol. 30. P. 1113–1118.

45. Majid A., Richards T., Dusanjh P., Kennedy D.B., Miall F., Gesk S. et al. TP53 codon 72 polymorphism in patients with chronic lymphocytic leukaemia: identification of a subgroup with mutated IGHV genes and poor clinical outcome // Br. J. Haematol. 2011. Vol. 153. P. 533–535.

46. Dong H.J., Fang C., Wang L., Fan L., Xu J., Wu J.Z. et al. TP53 Pro72 allele potentially increases the poor prognostic significance of TP53 mutation in chronic lymphocytic leukemia // Med. Oncol. 2014. Vol. 31. P. 908.

47. Sturm I., Bosanquet A.G., Hummel M., Dörken B., Daniel P.T. In B­CLL, the codon 72 polymorphic variants of p53 are not related to drug resistance and disease prognosis // BMC Cancer. 2005. Vol. 5. P. 105.

48. Soussi T., Leroy B., Taschner P.E. Recommendations for analyzing and reporting TP53 gene variants in the high­throughput sequencing era // Hum. Mutat. 2014. Vol. 35. P. 766–778.

49. Kalia S.S., Adelman K., Bale S.J., Chung W.K., Eng C., Evans J.P. et al. Recommendations for reporting of secondary findings in clinical exome and genome sequencing, 2016 update (ACMG SFv2.0): a policy statement of the American College of Medical Genetics and Genomics // Genet. Med. 2017. Vol. 19. P. 249–255.

50. Green R.C., Berg J.S., Grody W.W., Kalia S.S., Korf B.R., Martin C.L. et al. ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing // Genet. Med. 2013. Vol. 15. P. 565–574.

51. Supek F., Miñana B., Valcárcel J., Gabaldón T., Lehner B. Synonymous mutations frequently act as driver mutations in human cancers // Cell. 2014. Vol. 156. P. 1324–1335.

52. Varley J.M., Attwooll C., White G., McGown G., Thorncroft M., Kelsey A.M. et al. Characterization of germline TP53 splicing mutations and their genetic and functional analysis // Oncogene. 2001. Vol. 20. P. 2647–2654.

53. Landau D.A., Tausch E., Taylor­Weiner A.N., Stewart C., Reiter J.G., Bahlo J. et al. Mutations driving CLL and their evolution in progression and relapse // Nature. 2015. Vol. 526. P. 525–530.

54. Soussi T., Taschner P.E., Samuels Y. Synonymous somatic variants in human cancer are not infamous: a plea for full disclosure in databases and publications // Hum. Mutat. 2017. Vol. 38. P. 339–342.